rs12459419 — CD33 CD33 exon 2 splicing variant

Coding variant in CD33 (Siglec-3) that alters exon 2 splicing in microglia — the T allele promotes exon 2 skipping, producing a short CD33 isoform that lacks the sialic acid-binding IgV domain and enhances microglial phagocytosis of amyloid-beta, reducing Alzheimer's disease risk

See your personal result for CD33

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CD33 Exon 2 Splicing — The Microglial Phagocytosis Switch

CD33 (Siglec-3)11 CD33 (Siglec-3)
A sialic acid-binding immunoreceptor expressed on myeloid cells including microglia; member of the Siglec family that inhibits cellular activation through ITIM signaling domains is expressed abundantly on microglia, the brain's resident immune cells and primary clearers of amyloid-beta plaques. In Alzheimer's disease, microglia fail to efficiently engulf and degrade amyloid deposits — and CD33 is a key molecular brake on that process. The rs12459419 variant sits in exon 2 of CD33 and fundamentally changes how much of this brake is active in your microglia.

The Mechanism

CD33 exists in two functional isoforms determined by alternative splicing of exon 2. The full-length isoform (FL-CD33) contains the IgV domain22 IgV domain
The immunoglobulin V-set domain encoded by exon 2; responsible for binding sialic acid residues on adjacent cells; required for CD33's inhibitory signaling through ITIM motifs — a sialic acid-binding domain that allows CD33 to suppress microglial phagocytic activity via ITIM-mediated signaling. The short isoform (D2-CD33), produced when exon 2 is skipped during splicing, lacks this IgV domain entirely. Without the inhibitory domain, microglia carrying D2-CD33 are more active phagocytes — they internalize and degrade amyloid-beta more efficiently.

The rs12459419 T allele promotes exon 2 skipping, shifting the splicing balance toward more D2-CD33 transcript relative to FL-CD33. Each copy of the T allele reduces full-length CD33 expression by approximately 25%33 Each copy of the T allele reduces full-length CD33 expression by approximately 25%
Measured by qPCR of brain tissue and flow cytometry of peripheral monocytes in human samples stratified by rs12459419 genotype, raising the proportion of the phagocytosis-competent short isoform. The protective effect is additive: TT homozygotes have the greatest exon 2 skipping, CT heterozygotes intermediate, and CC homozygotes the least — maintaining the maximum inhibitory CD33 brake on microglial clearance activity.

The Evidence

The rs12459419 T allele was identified as the likely causal variant for the CD33 Alzheimer's GWAS signal originally detected at the promoter SNP rs386544444 rs3865444
Located ~515 bp upstream of the rs12459419 coding position; identified as an AD GWAS hit in multiple large studies but likely acts through LD with the functional exon 2 splicing variant. The two SNPs are in high linkage disequilibrium; fine-mapping experiments suggest rs12459419 is the causal functional change.

Alzheimer's disease protection: Malik et al. 201555 Malik et al. 2015
Human Molecular Genetics, multi-cohort analysis found that each T allele copy reduced the Alzheimer's disease odds ratio by approximately 0.10 per allele, with TT homozygotes showing the greatest protection. The effect is consistent across multiple independent cohorts and is biologically coherent: more exon 2 skipping → less FL-CD33 → less inhibition of microglial phagocytosis → more efficient amyloid clearance.

Direct functional validation: Bhattacherjee et al. 202166 Bhattacherjee et al. 2021
Molecular Neurodegeneration, PMID 33766097 demonstrated directly that the D2-CD33 isoform (the exon 2-skipped form) is a gain-of-function variant for microglial phagocytosis — microglia expressing D2-CD33 show significantly enhanced uptake of Aβ(1-42) compared to cells expressing full-length CD33. This makes rs12459419 one of the few Alzheimer's risk variants with a clear and directly demonstrated protective mechanism.

Evolutionary context: Schwarz et al. 201677 Schwarz et al. 2016
PNAS showed that the rs12459419 T allele and exon 2 skipping are evolutionarily derived, human-specific traits (absent in other great apes), and are associated with protection against post-reproductive cognitive decline. This evolutionary framing suggests the exon 2 splicing variant emerged specifically in the human lineage, possibly as an adaptation supporting longer cognitive health.

AML pharmacogenomics: The same rs12459419 T allele that reduces CD33 surface expression also determines response to gemtuzumab ozogamicin (Mylotarg), a CD33-targeting antibody–drug conjugate used in acute myeloid leukemia. CC homozygotes express more surface CD33 and respond better to gemtuzumab; TT homozygotes have lower CD33 surface density and may have reduced response. Lamba et al. 201788 Lamba et al. 2017
Journal of Clinical Oncology established rs12459419 as a predictive biomarker for gemtuzumab ozogamicin response — an independent clinical significance domain beyond Alzheimer's.

Practical Implications

For most people, this variant's primary relevance is Alzheimer's disease risk modification — specifically, whether your microglia are more or less capable of clearing amyloid-beta. The T allele confers measurable protection, but it is not a guarantee against Alzheimer's nor does its absence guarantee disease. APOE ε4 status, lifestyle factors, and numerous other genetic variants interact to shape overall risk.

For T allele carriers, the beneficial mechanism — enhanced microglial phagocytosis — can be further supported through strategies that maintain microglial function: omega-3 DHA adequacy (a key component of microglial membranes and phagocytic capacity) and management of factors known to impair microglial activity such as chronic neuroinflammation from metabolic syndrome or sleep apnea. For CC carriers (the modal genotype), monitoring cognitive health and addressing modifiable Alzheimer's risk factors earlier takes on added relevance given the reduced microglial phagocytic reserve.

Interactions

Rs12459419 is in high linkage disequilibrium with rs3865444, a promoter variant that was the original CD33 Alzheimer's GWAS signal. The two variants are typically co-inherited and fine-mapping suggests rs12459419 is the causal variant driving the GWAS association through splicing effects, while rs3865444 may contribute independently through altered CD33 promoter activity. In practice, most users will share the same allele pattern at both loci.

The CD33 phagocytosis pathway intersects with other microglial function genes implicated in Alzheimer's risk: TREM2, BIN1, CLU, CR1, and PICALM all converge on microglial amyloid handling. Individuals carrying both the CD33 CC risk genotype and TREM2 risk variants (e.g. rs75932628, R47H) would have two independent deficits in microglial amyloid clearance — a potential compound interaction worth noting.

Genotype Interpretations

What each possible genotype means for this variant.

CC Full-Length CD33 — Standard Phagocytosis Normal

Both alleles maintain full-length CD33 with its inhibitory IgV domain, providing standard microglial phagocytic capacity

The CC genotype produces the maximum amount of full-length CD33 relative to the phagocytosis-competent D2-CD33 short isoform. Full-length CD33 binds sialic acid residues on adjacent cells through its IgV domain and signals inhibitory messages via ITIM motifs, reducing the microglial phagocytic drive. In the context of amyloid accumulation, this means CC microglial cells are somewhat less efficient at clearing Aβ deposits compared to T allele-carrying microglia. This is a quantitative modulation, not an on/off switch — CC individuals do clear amyloid, but with modestly reduced efficiency per microglial cell compared to T allele carriers. The relative Alzheimer's risk elevation is modest and is best understood as the absence of the protective effect carried by the T allele rather than an active disease-causing mutation.

CT One Protective Allele — Enhanced Phagocytosis Beneficial

One T allele increases exon 2 skipping, reducing full-length CD33 expression by ~25% and modestly enhancing microglial amyloid clearance

The additive inheritance pattern means one T allele provides approximately half the splicing shift of two T alleles. In Malik et al. 2015, each T allele reduced the Alzheimer's disease odds ratio by approximately 0.10, so CT heterozygotes occupy an intermediate position between the standard CC and the maximally protective TT genotype. The functional basis — D2-CD33 isoform lacking the ITIM-signaling IgV domain — is the same in CT and TT carriers; it is a matter of degree. For the AML pharmacogenomics dimension: CT carriers have intermediate CD33 surface expression and intermediate gemtuzumab ozogamicin response compared to the CC (high response) and TT (potentially lower response) extremes. This is relevant only if being evaluated for AML treatment.

TT Homozygous Protective — Maximum Exon Skipping Beneficial

Two T alleles drive maximum exon 2 skipping, strongly reducing full-length CD33 and most strongly enhancing microglial amyloid phagocytosis

TT homozygosity represents the maximum protective end of the rs12459419 spectrum. Both copies of the exon 2-skipping allele work in concert to maximize D2-CD33 (short isoform) production at the expense of full-length FL-CD33. Bhattacherjee et al. 2021 directly demonstrated that microglia expressing D2-CD33 show significantly higher Aβ(1-42) phagocytosis than FL-CD33-expressing microglia — making this a gain-of-function protective mechanism rather than simply a loss-of-function attenuation.

The evolutionary context from Schwarz et al. 2016 is striking: the rs12459419 T allele is a human-specific derived allele absent in other great apes. It appears to have arisen and been maintained in the human lineage as an adaptation supporting extended post-reproductive cognitive health — the same period when Alzheimer's risk is highest. TT homozygotes represent the population subset carrying two copies of this evolutionarily derived protective trait.

In the AML pharmacogenomics context, TT carriers have the lowest surface CD33 expression in myeloid cells, which may reduce gemtuzumab ozogamicin efficacy. This is a potential adverse implication of the same splicing variant that protects cognitively — a trade-off relevant only in the specific clinical context of AML treatment.